

# UC San Diego

## UC San Diego Previously Published Works

### Title

Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis

### Permalink

<https://escholarship.org/uc/item/5hd6t56w>

### Journal

Nature Chemical Biology, 12(1)

### ISSN

1552-4450

### Authors

Green, CR  
Wallace, M  
Divakaruni, AS  
et al.

### Publication Date

2016

### DOI

10.1038/nchembio.1961

Peer reviewed

# Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis

Courtney R Green<sup>1</sup>, Martina Wallace<sup>1</sup>, Ajit S Divakaruni<sup>2</sup>, Susan A Phillips<sup>3,4</sup>, Anne N Murphy<sup>2</sup>, Theodore P Ciaraldi<sup>3,4</sup> & Christian M Metallo<sup>1,5\*</sup>

**Adipose tissue plays important roles in regulating carbohydrate and lipid homeostasis, but less is known about the regulation of amino acid metabolism in adipocytes. Here we applied isotope tracing to pre-adipocytes and differentiated adipocytes to quantify the contributions of different substrates to tricarboxylic acid (TCA) metabolism and lipogenesis. In contrast to proliferating cells, which use glucose and glutamine for acetyl-coenzyme A (AcCoA) generation, differentiated adipocytes showed increased branched-chain amino acid (BCAA) catabolic flux such that leucine and isoleucine from medium and/or from protein catabolism accounted for as much as 30% of lipogenic AcCoA pools. Medium cobalamin deficiency caused methylmalonic acid accumulation and odd-chain fatty acid synthesis. Vitamin B12 supplementation reduced these metabolites and altered the balance of substrates entering mitochondria. Finally, inhibition of BCAA catabolism compromised adipogenesis. These results quantitatively highlight the contribution of BCAAs to adipocyte metabolism and suggest that BCAA catabolism has a functional role in adipocyte differentiation.**

Adipose tissue has a major role in glucose and lipid homeostasis via the storage of excess nutrients in lipid droplets and the release of bioenergetic substrates through lipolysis. Adipocytes, the major cellular constituent of adipose tissue, execute important regulatory functions through endocrine and paracrine signaling<sup>1</sup>. For example, the synthesis and release of lipids and adipokines influence fatty acid metabolism in the liver, appetite, inflammation and insulin sensitivity<sup>2–4</sup>. Dysfunction in these pathways can contribute to insulin resistance<sup>5</sup>. Beyond these signaling functions, the increased adiposity associated with obesity and type 2 diabetes mellitus (T2DM) highlights the need to better understand metabolic regulation and activity in adipocytes.

Insulin stimulates glucose utilization and *de novo* lipogenesis (DNL) in the liver and adipose tissue, and glucose and fatty acids are considered the primary carbon sources fueling anaplerosis and AcCoA generation in these sites<sup>6</sup>. Beyond carbohydrates and fat, both essential and nonessential amino acids also contribute significantly to AcCoA metabolism in cells. The branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are important ketogenic and/or anaplerotic substrates in a number of tissues<sup>7,8</sup>. In fact, clinical metabolomics studies have recently suggested that plasma levels of BCAAs, their downstream catabolites (such as acylcarnitines) and other essential amino acids become elevated in the context of insulin resistance<sup>9–11</sup>. However, the mechanisms leading to these changes and their ultimate consequences in the context of metabolic syndrome are not fully understood.

Several past studies provide evidence that adipose tissue plays a role in BCAA homeostasis, though the quantitative contribution of these amino acids to TCA metabolism relative to those of other nutrients is not well defined. Enzyme activity, substrate oxidation and systems-based profiling of 3T3-L1 metabolism suggest that BCAA consumption increases precipitously during differentiation to adipocytes<sup>12–14</sup>. In addition, the transcription of BCAA catabolic enzymes increases significantly during 3T3-L1 differentiation<sup>15</sup>. Whereas genetic modulation of *Bcat2* in mice alters circulating

BCAA levels, transplantation of wild-type adipose tissue to *Bcat2*<sup>−/−</sup> mice normalizes plasma BCAAs<sup>16–18</sup>. Finally, treatment of human subjects and animals with thiazolidinediones (TZDs), clinically used activators of peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), increases the transcription of BCAA catabolic genes in adipose tissue<sup>19,20</sup>, suggesting that this metabolic activity may have beneficial effects in the context of T2DM.

To date, the extent to which oxidation of BCAAs, relative to other substrates, contributes to anaplerosis and DNL has not been quantitatively determined in adipocytes. Here we employed <sup>13</sup>C-labeled isotope tracers, mass spectrometry and isotopomer spectral analysis (ISA) to quantify BCAA utilization in proliferating pre-adipocytes and differentiated adipocytes. Whereas proliferating pre-adipocytes did not appreciably catabolize these substrates, BCAAs accounted for as much as one-third of the mitochondrial AcCoA in terminally differentiated 3T3-L1 adipocytes as well as in adipocytes isolated from human subcutaneous and visceral adipose tissues. Furthermore, inadequate cobalamin availability in 3T3-L1 cultures perturbed BCAA and fatty acid metabolism and led to the non-physiological accumulation of methylmalonate (MMA) and synthesis of odd-chain fatty acids (OCFAs). Finally, inhibition of BCAA catabolism negatively influenced 3T3-L1 adipogenesis. These results highlight the complex interplay between cellular differentiation and metabolic pathway flux in adipocyte biology.


## RESULTS

### Adipogenesis reprograms amino acid metabolism

To understand how mitochondrial substrate utilization changes during adipogenesis, we quantified the sources of lipogenic AcCoA before and after differentiation. 3T3-L1 adipocytes displayed substantial lipid accumulation 7 d after induction of differentiation (Supplementary Results, Supplementary Fig. 1a). Palmitate (total from saponified nonpolar extracts) in proliferating and differentiated 3T3-L1 cells cultured with [U-<sup>13</sup>C<sub>6</sub>]glucose (Supplementary Fig. 1b) had the expected pattern of labeling arising via pyruvate

<sup>1</sup>Department of Bioengineering, University of California, San Diego, La Jolla, California, USA. <sup>2</sup>Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. <sup>3</sup>Veterans Affairs San Diego Healthcare System, San Diego, California, USA. <sup>4</sup>Department of Medicine, University of California, San Diego, La Jolla, California, USA. <sup>5</sup>Institute of Engineering in Medicine, University of California, San Diego, La Jolla, California, USA.


\*e-mail: cmetallo@eng.ucsd.edu



**Figure 1 | Characterization of metabolic reprogramming during adipocyte differentiation.** (a) Contribution of  $[U-^{13}C_5]$ glutamine and  $[U-^{13}C_6]$ glucose to lipogenic AcCoA for palmitate synthesis in 143B, A549, HuH-7 cancer cells and 3T3-L1 pre-adipocytes and adipocytes. (b) Uptake and secretion fluxes in 3T3-L1 pre-adipocytes and adipocytes. (c) Percentage of intracellular glutamine, serine and glycine pools that were newly synthesized (labeled) from  $[U-^{13}C_6]$ glucose in 3T3-L1 pre-adipocytes and adipocytes. (d) Net amino acid uptake and secretion in 3T3-L1 pre-adipocytes and adipocytes. (e) Percentage of amino acids that contain an M1 label indicating transamination from the indicated  $[^{15}N]$ amino acid tracers. Data presented in **a** are model output  $\pm$  95% confidence interval (CI), and those in **b–e** are mean  $\pm$  s.d. Data shown in **a–e** are from three technical replicates (separate wells in cell culture) representative of three biological replicates (independent experiments); asterisks represent significant differences between groups by Student's two-tailed *t*-test: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

dehydrogenase (PDH)-mediated generation of M2 AcCoA (i.e., AcCoA containing two  $^{13}C$  isotopes). Isotopic enrichment from  $[U-^{13}C_5]$ glutamine (**Supplementary Fig. 1c**) was lower than that observed with labeled glucose. ISA was employed to quantify the relative contributions of  $[U-^{13}C_6]$ glucose and  $[U-^{13}C_5]$ glutamine to *de novo* palmitate synthesis in 3T3-L1 pre-adipocytes versus adipocytes and compared to results in cancer cell lines of various tissue origins (**Fig. 1a**). Notably, glucose and glutamine accounted for  $\geq 80\%$  of the lipogenic AcCoA in all proliferating cells. In contrast to cells with an active cell cycle, in differentiated cells a substantially greater fraction of lipid carbon arose from substrates other than glucose and glutamine. As expected, absolute lipogenic flux from glucose and glutamine to palmitate increased dramatically after differentiation (**Supplementary Fig. 1d**).

When normalized to protein levels, glucose uptake, lactate secretion and glutamine uptake were all significantly reduced in differentiated 3T3-L1 cells as compared to those at the pre-adipocyte stage (**Fig. 1b**). Proliferating 3T3-L1 pre-adipocytes secreted more lactate per mole of glucose taken up—a hallmark of rapidly proliferating cells<sup>21</sup>. Importantly, the use of stable isotope tracers allowed us to measure the percentage of each amino acid pool that was newly synthesized in each cell type. Despite their lack of proliferation, several nonessential amino acids initially present at high levels in the culture medium were synthesized at strikingly high rates in differentiated 3T3-L1 adipocytes, including glutamine, glycine and serine (**Fig. 1c**),




**Figure 2 | BCAA catabolism is initiated upon adipocyte differentiation.**

(a) Summary of BCAA catabolism and carbon-atom transitions from each BCAA tracer. Abbreviations: Bckdh, branched-chain ketoacid dehydrogenase; AcCoA, acetyl-CoA; PropCoA, propionyl-CoA. (b) Citrate labeling in 3T3-L1 adipocytes from  $[U-^{13}C_6]$ leucine and  $[U-^{13}C_6]$ isoleucine. (c) Mole percent enrichment (MPE) of citrate from each tracer substrate in 3T3-L1 pre-adipocytes and adipocytes. (d) MPE of citrate from  $[U-^{13}C_6]$ leucine and  $[U-^{13}C_6]$ isoleucine in primary human pre-adipocytes and adipocytes isolated from subcutaneous (SAT) or omental adipose tissue (OAT) depots. Data in **b–d** are from three technical replicates representative of three biological replicates and represent mean  $\pm$  s.d.; asterisks represent significant differences between groups by two-way ANOVA: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

whereas none of the proliferating cells tested synthesized glutamine *de novo*. After 24 h of culture in medium containing 4 mM glutamine, approximately 20% of the pool was newly synthesized, such that glutamine was secreted into the culture medium at a considerable rate (while still being consumed) (**Supplementary Fig. 1e**), in line with results from studies in adipose tissue<sup>22</sup>. Given that *de novo* synthesis of glutamine and other amino acids was occurring at significant rates in differentiated cells, we hypothesized that consumption of other amino acids increased upon differentiation to provide the necessary nitrogen for these reactions. Indeed, quantitation of amino acid fluxes indicated that BCAA consumption increased dramatically in differentiated 3T3-L1 adipocytes as compared to pre-adipocytes (**Fig. 1d**), consistent with previous observations<sup>13</sup>. Furthermore, metabolic tracing using  $^{15}N$ -labeled BCAAs indicated that nitrogen from these substrates contributed to amino acid synthesis in differentiated adipocytes (**Fig. 1e**).

### BCAAs fuel TCA metabolism and lipogenesis in adipocytes

To better quantify the extent to which leucine or isoleucine contribute to mitochondrial metabolism and lipogenesis in cultured adipocytes, we applied  $[U-^{13}C_6]$ leucine or  $[U-^{13}C_6]$ isoleucine tracers to 3T3-L1 cultures. **Figure 2a** summarizes the carbon atom transitions associated with BCAA catabolism and resultant labeling in mitochondrial intermediates. For a more detailed map of BCAA catabolism, see **Supplementary Figure 2a**. Two M2 AcCoA and one M1 AcCoA molecules are produced from  $[U-^{13}C_6]$ leucine catabolism, and  $[U-^{13}C_6]$ isoleucine catabolism yields one M2 AcCoA and one M3 propionyl-CoA (PropCoA), which is subsequently converted to succinyl-CoA. AcCoA molecules arising from leucine and isoleucine were readily incorporated into citrate pools in differentiated adipocytes (**Fig. 2b**). To compare changes before and



**Figure 3 | BCAA catabolism fuels mitochondrial metabolism and lipogenesis in adipocytes.** (a) Substrate-specific oxygen consumption rate (OCR) in permeabilized 3T3-L1 pre-adipocytes and adipocytes. Substrate key: M, malate; KIC-M, ketoisocaproate and malate; KMV-M, ketomethylvalerate and malate; KIV, ketoisovalerate; P-M, pyruvate and malate; S-R, succinate and rotenone; G-M, glutamate and malate. 250 nM AdoCbl and biotin were added to the respirometry medium. (b) Palmitate labeling in 3T3-L1 adipocytes from  $[U-^{13}C_6]$ leucine and  $[U-^{13}C_6]$ isoleucine. Minimal label was detected in palmitate from  $[U-^{13}C_5]$ valine. (c) Contribution of each tracer substrate to lipogenic AcCoA in 3T3-L1 pre-adipocytes and adipocytes after correction due to tracer dilution. BCAA contributions were adjusted to account for dilution of intracellular amino acids from protein turnover using the average BCAA labeling over the course of the experiment. Data presented in **a** are mean  $\pm$  s.e.m., data in **b** are mean  $\pm$  s.d. and data in **c** are model output  $\pm$  95% CI. Data in **a** represent at least five biological replicates each with four technical replicates, while those in **b** and **c** are three technical replicates representative of three biological replicates. \* $P < 0.05$ , \*\* $P < 0.01$  by Student's two-tailed *t*-test.

after differentiation, 3T3-L1 pre-adipocytes and those differentiated for 6–7 d were cultured in the presence of  $[U-^{13}C_6]$ glucose,  $[U-^{13}C_5]$ glutamine,  $[U-^{13}C_6]$ leucine or  $[U-^{13}C_6]$ isoleucine and the steady-state mole percent enrichment (MPE) in the citrate pool was measured (Fig. 2c and Supplementary Fig. 2b). Although incorporation of carbon atoms from leucine and isoleucine into citrate was barely detectable in pre-adipocytes, their contribution increased considerably upon adipocyte differentiation to 3.3% and 3.0%, respectively (Fig. 2c). Other TCA intermediates showed comparable levels of leucine and isoleucine enrichment (Supplementary Fig. 2c), beginning about 2 d into differentiation (Supplementary Fig. 2d).

We also quantified the relative extent of BCAA catabolism in human pre-adipocytes isolated from subcutaneous or omental depots to observe whether induction of BCAA catabolism also occurs during human adipogenesis<sup>23–25</sup>. Trends observed when comparing citrate MPE from both  $[U-^{13}C_6]$ leucine and  $[U-^{13}C_6]$ isoleucine in human pre-adipocytes as compared to differentiated adipocytes were similar to those observed in 3T3-L1 cells, suggesting that human adipocytes also metabolize BCAAs at higher rates than human pre-adipocytes (Fig. 2d).


In addition to carbon atom enrichment, evidence of the oxidative capacity of these cells for each of the respective branched-chain ketoacids (BCKAs) was obtained via respirometry analysis of permeabilized adipocytes<sup>26,27</sup>. When comparing uncoupler-stimulated respiration of adipocytes and pre-adipocytes, we observed a marked increase in oxygen consumption from all substrates tested, but a disproportionate increase in the oxidation of the BCAT2 reaction products ketoisocaproate (KIC), ketomethylvalerate (KMV) and ketoisovalerate (KIV) was evident (Fig. 3a). The capacity to oxidize these BCKAs increased by 14- to 25-fold after differentiation, a much greater increase than was observed for other substrates, suggesting that differentiation-induced mitochondrial biogenesis does not entirely explain the increased capacity to oxidize BCKAs (Supplementary Fig. 3a).

In contrast to cultured human adipocytes, 3T3-L1 cells exhibit high levels of DNL, which facilitates quantitation of isotope enrichment in the lipogenic AcCoA pool (Fig. 3b). To determine the relative contributions of  $[U-^{13}C_6]$ glucose,  $[U-^{13}C_5]$ glutamine,  $[U-^{13}C_6]$ leucine and  $[U-^{13}C_6]$ isoleucine to this metabolic pool, we modified our ISA model to account for partially labeled AcCoA arising from  $[U-^{13}C_6]$ leucine catabolism (Fig. 2a and Supplementary Table 1). The contributions of both glucose and glutamine to AcCoA decreased significantly upon differentiation (Fig. 3c). On the other hand, leucine and isoleucine contributions increased from undetectable levels in pre-adipocytes to 23% and 9%, respectively, in adipocytes.

These results are consistent with the pronounced induction of BCAA oxidation we observed upon adipocyte differentiation. Finally, this metabolic reprogramming toward BCAA utilization dramatically increased 3 d after induction and continued until 6 d after induction (Supplementary Fig. 3b), coinciding with the accumulation of palmitate and other fatty acids (Supplementary Fig. 3c).

### Protein catabolism supports BCAA metabolism

Elevated nutrient concentrations can influence metabolic activity through mass action or the regulation of cell signaling pathways, particularly in the case of glucose and BCAAs<sup>28</sup>. Indeed, BCAA levels in standard adipocyte medium (that is, DMEM) are over four-fold higher than those measured in human and mouse plasma<sup>9</sup>. To test whether the high concentrations of amino acids and glucose in 3T3-L1 cultures influences the extent of BCAA catabolism, we cultured adipocytes in medium with glucose and the full complement of amino acids present at more physiological levels (termed 'Low gluc+AA'—for example, 6 mM glucose, 1 mM glutamine and 200  $\mu$ M for each BCAA; see Supplementary Table 2 for complete formulation). In comparing the metabolism of 3T3-L1 adipocytes in control versus Low gluc+AA media, we observed a significant reduction in glycolysis and amino acid uptake and secretion (Fig. 4a,b). On the other hand, total fatty acid pools and synthesis rates were unchanged (Supplementary Fig. 4a,b). ISA using specific tracers indicated that the contribution of glucose to AcCoA increased, while the relative contribution of BCAAs to fatty acids decreased (Fig. 4c). Notably, the increased glucose contribution could be almost entirely accounted for by increased labeling of glutamine from glucose (Supplementary Fig. 4c). Perhaps more importantly, the decrease in BCAA-derived label in AcCoA pools was strongly affected by dilution from unlabeled protein turnover (the only other source of essential amino acids present): within 24 h, approximately 50% of the intracellular BCAA pool became unlabeled (Fig. 4d). Notably, the final concentrations of each BCAA (25  $\mu$ M leucine, 40  $\mu$ M isoleucine and 75  $\mu$ M valine) were well below those observed in plasma from fasting human subjects<sup>29</sup> (125  $\mu$ M leucine, 75  $\mu$ M isoleucine and 200  $\mu$ M valine), which would strongly induce protein catabolism at the end of culture. However, these data provide evidence that amino acids (BCAAs in particular) from both extracellular sources and protein catabolism are highly utilized by differentiated adipocytes. Though not surprising given the coordinate regulation of protein synthesis and catabolism<sup>30</sup>, the marked dilution of  $[^{13}C]$ BCAAs observed here highlights the importance of amino acid recycling in metabolically active cells and tissues.




**Figure 4 | BCAA utilization is supported by protein catabolism.**

(a) Uptake and secretion fluxes in 3T3-L1 adipocytes cultured in control and Low gluc+AA media. (b) Amino acid uptake and secretion in control and Low gluc+AA media. (c) Contribution of each tracer to lipogenic AcCoA in 3T3-L1 adipocytes cultured in control and Low gluc+AA media. BCAA contributions were adjusted to account for dilution of intracellular amino acids from protein turnover using the average BCAA labeling over the course of the experiment. Glutamine dilution occurred primarily via glucose-derived synthesis. (d) Percentage of pool without label when cultured in indicated tracer substrate in control and Low gluc+AA for 24 h. Data presented in **a,b,d** are mean  $\pm$  s.d.; data in **c** are model output  $\pm$  95% CI. Data shown in **a-d** are from three technical replicates representative of three biological replicates; \*\* $P < 0.01$ , \*\*\* $P < 0.001$  by Student's two-tailed *t*-test.

### Medium B12 deficiency affects BCAA and lipid metabolism

Intriguingly, we failed to observe prominent M3 labeling of citrate (Fig. 2b) or other TCA intermediates (data not shown) when culturing differentiated 3T3-L1 cells with  $[U-^{13}C_6]$ isoleucine, suggesting that PropCoA and methylmalonyl CoA (MMA-CoA) derived from isoleucine did not enter the TCA cycle (Supplementary Fig. 2a). We also failed to detect  $^{13}C$  incorporation in any TCA metabolite from  $[U-^{13}C_5]$ valine (data not shown). Notably, we measured substantial accumulation of methylmalonic acid (MMA) in differentiated 3T3-L1 cells, which was surprisingly present at intracellular levels similar to those of BCAAs (Supplementary Fig. 5a). Furthermore, high levels of OCFAs accumulated in 3T3-L1 adipocytes but not pre-adipocytes, including C15:0 and C17:0 species (Fig. 5a). These fatty acids have previously been observed in other reports using 3T3-L1 cells, but their origin has remained unclear<sup>31</sup>.

Distinct M3 labeling was observed in MMA after 24 h of culture with  $[U-^{13}C_6]$ isoleucine or  $[U-^{13}C_5]$ valine (Supplementary Fig. 5b), as expected on the basis of known pathway architecture. Similarly, the C15:0 and C17:0 OCFAs also contained a prominent M3 peak after culture with these BCAA tracers (Fig. 5b and Supplementary Fig. 5c), providing evidence that these fatty acids arose from BCAA-derived DNL rather than via  $\alpha$ -oxidation. These data suggest that



**Figure 5 | BCAAs contribute to MMA, OCFAs and BCFAs in differentiated 3T3-L1 adipocytes.**


(a) Odd-chain fatty acid (OCA) accumulation in 3T3-L1 adipocytes 0–7 d after induction. (b) C17:0 labeling from  $[U-^{13}C_6]$ isoleucine and  $[U-^{13}C_5]$ valine in 3T3-L1 adipocytes. (c) MMA abundance in cells cultured in DMEM +10% FBS and 0, 2, 8, 32, 125 or 500 nM cobalamin beginning on day 0 of differentiation. (d) OCFAs levels in 3T3-L1 adipocytes after culture with 500 nM cobalamin or 100 nM AdoCbl. \*\*\* $P < 0.001$  compared to control condition by two-way ANOVA and Holm-Sidak's multiple-comparison test. (e) Relative abundance of the most abundant fatty acids in control and + cobalamin conditions. \*\*\* $P < 0.001$  compared to control condition by Student's two-tailed *t*-test. (f) Uptake of BCAAs in control and + cobalamin condition. Data presented in **a-f** are mean  $\pm$  s.d. and represent three technical replicates representative of three biological replicates.

MMA and PropCoA accumulate in differentiated 3T3-L1 adipocytes, presumably due to defects in BCAA catabolism.

MMA accumulates in patients with the genetic disorder methylmalonic aciduria. This phenotype may be caused by mutations in the gene encoding MMA-CoA mutase (*MUT*) or genes involved in cobalamin metabolism, as the conversion of MMA-CoA to succinyl-CoA requires the coenzyme 5'-deoxyadenosylcobalamin (AdoCbl)<sup>32</sup>. Notably, the human adipocytes analyzed in this study were cultured in DMEM/F12, which contains 500 nM cobalamin, and both OCFAs and MMA were undetectable in these cultures. Because typical 3T3-L1 culture conditions employ DMEM lacking cobalamin, and supplementation with 10% dialyzed or untreated serum might not be sufficient to support this metabolism, we hypothesized that deficiencies in cobalamin availability led to the accumulation of MMA and OCFAs. Indeed, addition of cobalamin to media at levels ranging from 2 nM (the approximate concentration in human plasma) to 500 nM (DMEM/F12) prevented the accumulation of these metabolites (Fig. 5c and Supplementary Fig. 5d). We obtained similar results when we added cobalamin or AdoCbl to 3T3-L1 culture medium (Supplementary Fig. 5e and Fig. 5d).

Supplementation of cobalamin influenced the relative abundance of fatty acid species as well as the contribution of BCAAs to TCA metabolism. For example, addition of cobalamin from day 0





**Figure 6 | Inhibition of BCAA catabolism impairs adipocyte differentiation.** (a) Western blot of *Bckdha* and  $\beta$ -actin in differentiated 3T3-L1 adipocytes. Full gel is shown in **Supplementary Figure 6**. (b) Basal respiration in control and *Bckdha* KD adipocytes (two cell lines separately derived using unique hairpins) normalized to nuclear quantitation. Data are from four technical replicates representative of three biological replicates. (c) BCAA uptake in control KD and *Bckdha* KD adipocytes. (d) Absolute lipogenic flux of leucine to palmitate synthesis. (e) Relative abundance of the most abundant fatty acids. (f) Quantitative PCR analysis of adipocyte-specific gene expression. (g) Representative images of adipocyte differentiation (scale bars, 200  $\mu$ m). From left: control KD, *Bckdha* KD1, *Bckdha* KD2. Data presented in **b–f** are mean  $\pm$  s.d. Asterisks in **b–e** represent significance compared to control KD: \* $P < 0.05$ , \*\* $P < 0.01$ , † $P < 0.001$ . Unless otherwise specified, data are from three technical replicates representative of three (**a–e**) or two (**f**) biological replicates (independent lentiviral knockdown and differentiation such that KD1 and KD2 were each derived two or three times) analyzed by two-way ANOVA with Holm-Sidak's multiple-comparison test.

to day 7 of differentiation reduced OCFAs levels as a percentage of the total intracellular fatty acids, with a concomitant increase occurring in the relative amount of palmitate (**Fig. 5e**). At the same time, cobalamin supplementation promoted anaplerosis of valine, as evidenced by increased enrichment of fumarate, malate and other TCA intermediates from [ $U$ - $^{13}C_6$ ]valine (**Supplementary Fig. 5f–h**). Furthermore, 3T3-L1 adipocytes took up more BCAAs, including leucine, when cultured in cobalamin-supplemented medium (**Fig. 5f**), suggesting that cobalamin deficiency and/or the accumulation of MMA and OCFAs results in broader regulation of the pathway. On the other hand, enrichment from [ $U$ - $^{13}C_6$ ]glucose decreased across all TCA intermediates in 3T3-L1 adipocytes cultured with 500 nM cobalamin (**Supplementary Fig. 5i**). These data indicate that accumulation of MMA, OCFAs and presumably their precursor, PropCoA, due to inadequate cobalamin availability perturbs BCAA, fatty acid and mitochondrial metabolism in cultured adipocytes.

### BCAA metabolism contributes to adipogenesis

Given the high catabolic flux of BCAAs observed in differentiated adipocytes, we next examined whether this pathway plays a functional role in adipogenesis. To address this question, we generated polyclonal populations of 3T3-L1 cells that stably express either short hairpin RNAs (shRNAs) targeting *Bckdha* (knockdown (KD) using one of two unique sequences) or nonspecific sequences (control). At confluence these cells were subjected to differentiation in the absence of cobalamin and rosiglitazone and each characterized with respect to their metabolism, morphology and differentiation markers. After differentiation, *Bckdha* KD cells exhibited lower *Bckdha* protein levels than control cells (**Fig. 6a**). Respiration and BCAA uptake were also significantly lower in KD cells than in controls (**Fig. 6b,c**). Consistent with this observation, lipogenic flux of [ $U$ - $^{13}C_6$ ]leucine to fatty acids was markedly lower in KD cells (**Fig. 6d**). Furthermore, the abundance of numerous fatty acids was decreased in differentiated KD cells, including fatty acids synthesized *de novo* as well as those taken up from the medium (**Fig. 6e**).

Finally, the transcription of selected adipogenic genes (*Pparg*, *Glut4*, *Plin4*, *Adipoq* and *Lep*) was significantly lower in the KD condition than in the control cells (**Fig. 6f**), further suggesting that BCAA catabolism contributes to adipogenesis. Representative images of differentiated cultures also suggested that *Bckdha* KD negatively affected adipogenic differentiation, as evidenced by decreased lipid droplet formation (**Fig. 6g**). Supplementation of cobalamin did not observably affect adipogenic differentiation (data not shown), suggesting that some metabolite or pathway flux upstream of MMA-CoA mutase contributes to adipogenesis.

### DISCUSSION

Here we have explored how specific nutrients differentially contribute to mitochondrial metabolism as a function of adipocyte differentiation. Human and mouse cell lines of diverse tissue origins, including human visceral and subcutaneous pre-adipocytes, predominantly obtained AcCoA for DNL from glucose and glutamine when proliferating. Upon differentiation, the relative conversion of glucose and glutamine carbon to fatty acids was reduced, while significant *de novo* glutamine synthesis was initiated. At the same time, differentiated adipocytes catabolized BCAAs such that leucine and isoleucine accounted for approximately one-third of lipogenic AcCoA. Even in the presence of more physiological concentrations of BCAAs, this catabolism was sustained via protein catabolism, as significant dilution arising from protein turnover was observed in differentiated adipocytes. These data indicate that proteinogenic amino acids serve as a significant carbon source for mitochondrial metabolism (and DNL) in differentiated adipocytes, a result similar to those obtained with pancreatic cancer cells cultured in low-glutamine medium<sup>33</sup>.

The suppression of BCAA catabolism during cell proliferation is consistent with the dedicated utilization of these nutrients for protein biosynthesis. Mammalian target of rapamycin (mTOR) activity and associated protein translation required for proliferation is sensitive to leucine availability in particular<sup>28,34</sup>. The differentiation-dependent induction of BCAA catabolism in 3T3-L1 cells and

human pre-adipocytes demonstrated here may therefore serve as a model system for identifying key activators or suppressors of BCAA metabolism. Activity of PPAR $\gamma$ , a target of TZDs, increases significantly during early adipogenesis and has recently been associated with BCAA catabolic enzyme expression in human tissues, animals and cell models<sup>13,15,19,20</sup>. However, additional transcription factors and coactivators driving this process may be identified through more systematic analyses.

Our results also demonstrate the critical role of vitamins as enzyme cofactors in mediating important metabolic processes and highlight potential deficiencies that could affect various model systems. In our hands and in other published studies, differentiated 3T3-L1 cells accumulated significant levels of OCFAs<sup>31</sup>. We confirmed that these metabolites arose from the accumulation of PropCoA and extension by fatty acid synthase (FASN) rather than  $\alpha$ -oxidation<sup>35</sup>. Supplementation of cobalamin suppressed OCFA and MMA abundances in culture, suggesting that 3T3-L1 cells have the appropriate mitochondrial machinery for converting cobalamin to the activated AdoCbl cofactor necessary for MUT activity. Given the severe pathologies associated with acute, untreated methylmalonic aciduria<sup>36</sup>, our results highlight the importance of investigating mitochondrial function as it correlates with cobalamin availability in other cell types that catabolize BCAAs. These findings also demonstrate that standard culture conditions for differentiated 3T3-L1 cells are inadequate to support complete BCAA oxidation. Indeed, the heart, muscle and kidney are known to metabolize BCAAs and may be particularly affected by deficiencies in this cofactor<sup>7,8,37</sup>. Numerous biological models that are routinely used to represent these tissues (such as rat cardiomyocytes, primary murine myocytes and adipocytes) employ media that may lack sufficient cobalamin for BCAA catabolism, as has been observed in glial cells<sup>38</sup>. MMA and OCFA accumulation may affect results obtained from such systems given the demonstrated pathology associated with these metabolites<sup>39</sup>.

Elevated plasma BCAAs, methionine and OCFAs, as well as C3- and C5-acylcarnitine species, have all been associated with obesity and insulin resistance<sup>40,41</sup>. Although biotin availability is hypothesized to be a potential unifying cause of perturbations in these pathways<sup>10</sup>, cobalamin-deficiency might also compromise BCAA catabolism in a similar manner to biotin. Indeed, a recent flux model of adipocyte metabolism that incorporated clinical proteomic and transcriptional data identifies MMA-CoA conversion to succinyl-CoA as a pathway that is downregulated in obese as compared to lean patients<sup>42</sup>. We observed that cobalamin deficiency induces the accumulation of downstream intermediates arising from BCAA catabolism (carnitine is also notably limited in culture systems employing dialyzed serum). Notably, several studies indicate that patients with T2DM are commonly deficient in cobalamin as a result of malabsorption due to metformin or other causes<sup>43,44</sup>. Furthermore, the expression of cobalamin transporters and cobalamin availability itself can influence the composition of the gut microbiome<sup>45</sup>, highlighting the complexity of the ways in which this cofactor can affect human health.

While BCAA catabolism is clearly induced during adipogenesis, functional knockdown of the pathway in pre-adipocytes impaired lipid accumulation and differentiation. These data provide the first direct evidence that BCAA oxidation is important for adipogenic differentiation. Presumably, some metabolite(s) along the BCAA catabolic pathway that are upstream of PropCoA and AcCoA could mediate the observed effects on adipogenesis, though additional studies are required to identify such a regulatory effect. Our demonstration of a link between BCAA catabolism and adipogenesis is consistent with previous observations in *Bcat2*<sup>-/-</sup> mice, which exhibit decreased adiposity among other metabolic changes<sup>16-18</sup>. These results may also provide insights into potential adipose-mediated pathogenesis in patients with maple syrup urine disease

(MSUD). However, cell-autonomous BCAA catabolism is likely not a prerequisite for adipogenic differentiation, as demonstrated by the moderate effects noted here and the (relative) health of individuals with MSUD. Collectively, our quantitative findings highlight critical roles for BCAA catabolism and vitamin availability in adipocyte differentiation, lipogenesis and bioenergetics.

Received 10 March 2015; accepted 7 October 2015;  
published online 16 November 2015

## METHODS

Methods and any associated references are available in the [online version of the paper](#).

## References

- Rosen, E.D. & Spiegelman, B.M. What we talk about when we talk about fat. *Cell* **156**, 20–44 (2014).
- Steppan, C.M. *et al.* The hormone resistin links obesity to diabetes. *Nature* **409**, 307–312 (2001).
- Glass, C.K. & Olefsky, J.M. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell Metab.* **15**, 635–645 (2012).
- Turer, A.T. & Scherer, P.E. Adiponectin: mechanistic insights and clinical implications. *Diabetologia* **55**, 2319–2326 (2012).
- Herman, M.A. *et al.* A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. *Nature* **484**, 333–338 (2012).
- Kahn, B.B. & Flier, J.S. Obesity and insulin resistance. *J. Clin. Invest.* **106**, 473–481 (2000).
- Buse, M.G., Biggers, J.F., Friderici, K.H. & Buse, J.F. Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat. The effect of fatty acids, glucose, and pyruvate respiration. *J. Biol. Chem.* **247**, 8085–8096 (1972).
- Rosenthal, J., Angel, A. & Farkas, J. Metabolic fate of leucine: a significant sterol precursor in adipose tissue and muscle. *Am. J. Physiol.* **226**, 411–418 (1974).
- Newgard, C.B. *et al.* A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* **9**, 311–326 (2009).
- Fiehn, O. *et al.* Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. *PLoS ONE* **5**, e15234 (2010).
- Wang, T.J. *et al.* Metabolite profiles and the risk of developing diabetes. *Nat. Med.* **17**, 448–453 (2011).
- Kedishvili, N.Y., Popov, K.M., Jaskiewicz, J.A. & Harris, R.A. Coordinated expression of valine catabolic enzymes during adipogenesis: analysis of activity, mRNA, protein levels, and metabolic consequences. *Arch. Biochem. Biophys.* **315**, 317–322 (1994).
- Si, Y., Yoon, J. & Lee, K. Flux profile and modularity analysis of time-dependent metabolic changes of de novo adipocyte formation. *Am. J. Physiol. Endocrinol. Metab.* **292**, E1637–E1646 (2007).
- Chuang, D.T., Hu, C.W. & Patel, M.S. Induction of the branched-chain 2-oxo acid dehydrogenase complex in 3T3-L1 adipocytes during differentiation. *Biochem. J.* **214**, 177–181 (1983).
- Lackey, D.E. *et al.* Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. *Am. J. Physiol. Endocrinol. Metab.* **304**, E1175–E1187 (2013).
- She, P. *et al.* Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. *Cell Metab.* **6**, 181–194 (2007).
- Herman, M.A., She, P., Peroni, O.D., Lynch, C.J. & Kahn, B.B. Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. *J. Biol. Chem.* **285**, 11348–11356 (2010).
- Zimmerman, H.A., Olson, K.C., Chen, G. & Lynch, C.J. Adipose transplant for inborn errors of branched chain amino acid metabolism in mice. *Mol. Genet. Metab.* **109**, 345–353 (2013).
- Sears, D.D. *et al.* Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. *Proc. Natl. Acad. Sci. USA* **106**, 18745–18750 (2009).
- Hsiao, G. *et al.* Multi-tissue, selective PPAR $\gamma$  modulation of insulin sensitivity and metabolic pathways in obese rats. *Am. J. Physiol. Endocrinol. Metab.* **300**, E164–E174 (2011).
- Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **324**, 1029–1033 (2009).
- Kowalski, T.J. & Watford, M. Production of glutamine and utilization of glutamate by rat subcutaneous adipose tissue in vivo. *Am. J. Physiol.* **266**, E151–E154 (1994).

23. Tchkonina, T. *et al.* Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. *Am. J. Physiol. Endocrinol. Metab.* **288**, E267–E277 (2005).
24. Lee, M.-J.J., Wu, Y. & Fried, S.K. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. *Mol. Aspects Med.* **34**, 1–11 (2013).
25. Phillips, S.A., Ciaraldi, T.P., Oh, D.K., Savu, M.K. & Henry, R.R. Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. *Am. J. Physiol. Endocrinol. Metab.* **295**, E842–E850 (2008).
26. Divakaruni, A.S., Rogers, G.W. & Murphy, A.N. Measuring mitochondrial function in permeabilized cells using the Seahorse XF analyzer or a Clark-type oxygen electrode. *Curr. Protoc. Toxicol.* **60**, 25.2.1–25.2.16 (2014).
27. Divakaruni, A.S. *et al.* Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. *Proc. Natl. Acad. Sci. USA* **110**, 5422–5427 (2013).
28. Nicklin, P. *et al.* Bidirectional transport of amino acids regulates mTOR and autophagy. *Cell* **136**, 521–534 (2009).
29. Cynober, L.A. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. *Nutrition* **18**, 761–766 (2002).
30. Zhang, Y. *et al.* Coordinated regulation of protein synthesis and degradation by mTORC1. *Nature* **513**, 440–443 (2014).
31. Roberts, L.D., Virtue, S., Vidal-Puig, A., Nicholls, A.W. & Griffin, J.L. Metabolic phenotyping of a model of adipocyte differentiation. *Physiol. Genomics* **39**, 109–119 (2009).
32. Kapadia, C.R. Vitamin B12 in health and disease: part I—inherited disorders of function, absorption, and transport. *Gastroenterologist* **3**, 329–344 (1995).
33. Commisso, C. *et al.* Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. *Nature* **497**, 633–637 (2013).
34. Lynch, C.J. *et al.* Potential role of leucine metabolism in the leucine-signaling pathway involving mTOR. *Am. J. Physiol. Endocrinol. Metab.* **285**, E854–E863 (2003).
35. Su, X. *et al.* sequential ordered fatty acid  $\alpha$ -oxidation and  $\Delta 9$  desaturation are major determinants of lipid storage and utilization in differentiating adipocytes. *Biochemistry* **43**, 5033–5044 (2004).
36. Haarmann, A. *et al.* Renal involvement in a patient with cobalamin A type (cblA) methylmalonic aciduria: a 42-year follow-up. *Mol. Genet. Metab.* **110**, 472–476 (2013).
37. Birn, H. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. *Am. J. Physiol. Renal Physiol.* **291**, F22–F36 (2006).
38. Barley, F.W., Sato, G.H. & Abeles, R.H. An effect of vitamin B12 deficiency in tissue culture. *J. Biol. Chem.* **247**, 4270–4276 (1972).
39. Kishimoto, Y., Williams, M., Moser, H.W., Hignite, C. & Biemann, K. Branched-chain and odd-numbered fatty acids and aldehydes in the nervous system of a patient with deranged vitamin B12 metabolism. *J. Lipid Res.* **14**, 69–77 (1973).
40. Newgard, C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. *Cell Metab.* **15**, 606–614 (2012).
41. Adams, S.H. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. *Adv. Nutr.* **2**, 445–456 (2011).
42. Mardinoglu, A. *et al.* Integration of clinical data with a genomescale metabolic model of the human adipocyte. *Mol. Syst. Biol.* **9**, 649 (2013).
43. Reinstatler, L., Qi, Y.P., Williamson, R.S., Garn, J.V. & Oakley, G.P. Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999–2006. *Diabetes Care* **35**, 327–333 (2012).
44. Kang, D. *et al.* Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study. *PLoS ONE* **9**, e109878 (2014).
45. Degnan, P.H., Barry, N.A., Mok, K.C., Taga, M.E. & Goodman, A.L. Human gut microbes use multiple transporters to distinguish vitamin B<sub>12</sub> analogs and compete in the gut. *Cell Host Microbe* **15**, 47–57 (2014).

## Acknowledgments

We thank R.R. Henry (R.R.H.; Veterans Affairs San Diego Healthcare System, San Diego, California, USA) for human adipocyte material. This work was supported, in part, by US National Institutes of Health (NIH) grant R01CA188652 (C.M.M.), California Institute of Regenerative Medicine (CIRM) Award RB5-07356 (C.M.M.), US Department of Defense (DOD) grant W81XWH-13-1-0105 (C.M.M.) and a Searle Scholar Award (C.M.M.), as well as grants from the American Diabetes Association (7-05-DCS-04), the Medical Research Service (1 I010X00635-01A1), the US Department of Veterans Affairs and the VA San Diego Healthcare System (R.R.H.), NIH grant 1R01NS087611 (A.N.M.) and a grant from Seahorse Bioscience.

## Author contributions

S.A.P. and T.P.C. obtained biopsies and isolated human pre-adipocytes from adipose tissue; A.S.D. and A.N.M. performed oxygen consumption experiments; C.R.G. and M.W. performed all other experiments. C.R.G., M.W., A.S.D., A.N.M., T.P.C. and C.M.M. designed research; C.R.G., M.W. and C.M.M. wrote the paper with help from all authors.

## Competing financial interests

The authors declare no competing financial interests.

## Additional information

Any supplementary information, and source data are available in the [online version of the paper](#). Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>. Correspondence and requests for material should be addressed to C.M.M.



## ONLINE METHODS

**Imaging.** A 0.35% (w/v) Oil Red O stock was prepared in isopropanol and filtered through a 0.22  $\mu\text{m}$  filter. Cells were washed with PBS, fixed with 4% paraformaldehyde for 30 min at room temperature, washed 2 $\times$  in milli-Q water, washed once with 60% isopropanol, and finally stained with 3:2 (stock:water) solution for 30 min. Stain solution was removed from cells and cells were washed 4 $\times$  with milli-Q water.

**Pre-adipocyte isolation.** All procedures for AT explant culture were carried out using sterile techniques. Fresh SAT was minced and placed into a 4% BSA/HEPES salts buffer containing 333 units collagenase (Worthington Biochemical Corp.) per ml buffer (~1,000 units per gram of AT) and incubated for 1 h in a 37  $^{\circ}\text{C}$  shaking water bath. Following digestion, the suspension was filtered through a 450  $\mu\text{m}$  nylon mesh (Component Supply Company) and centrifuged at 50g for 10 min at 25  $^{\circ}\text{C}$ . The pellet and infranant containing the SVF was aspirated and centrifuged through 250  $\mu\text{m}$  nylon mesh, then centrifuged at 800g for 10 min at 20  $^{\circ}\text{C}$ . Further pre-adipocyte isolation and culture was performed as previously described<sup>23</sup>.

**Respirometry.** Respirometry was conducted using a Seahorse XF96 Analyzer. For respiration in intact cells, cells were plated at  $5 \times 10^3$  cells/well and maintained and differentiated as described above. 10 days after differentiation was initiated, growth medium was replaced with unbuffered DMEM (Sigma #5030) supplemented with 8 mM glucose, 3 mM glutamine, 1 mM pyruvate and 0.5 mM carnitine. Mitochondrial respiration is calculated as the oxygen consumption rate sensitive to 1  $\mu\text{M}$  rotenone and 2  $\mu\text{M}$  antimycin A. Immediately after the experiment, rates were normalized for cell number using CyQuant (Life Technologies) and scaled appropriately.

For respiration in permeabilized cells, cells were seeded onto XF96 plates at  $1 \times 10^4$  cells/well and were maintained and differentiated as described above. Measurements of differentiated cells were conducted 10–14 days after differentiation was initiated. Respiration was initially measured in MAS medium supplemented with 0.2% (w/v) BSA, 4 mM ADP and 3 nM recombinant Perfringolysin O (purchased as XF Plasma Membrane Permeabilizer, Seahorse Bioscience)<sup>26</sup> and sequentially offered 2  $\mu\text{g}/\text{ml}$  oligomycin, successive additions of 2  $\mu\text{M}$  FCCP, and 2  $\mu\text{M}$  antimycin A. Permeabilized adipocytes were offered 5 mM branched chain ketoacids with 0.5 mM malate (except KIV, for which only  $\text{FADH}_2$ -linked respiration was measured) and concentrations for commonly used respiratory substrates are as described previously<sup>27</sup>. Uncoupler-stimulated respiration was calculated as the difference between the maximum respiratory rate in response to FCCP that was sensitive to antimycin A. All data were normalized to total cell protein as measured by the bicinchoninic acid assay (Pierce) with matched plates of whole cells.

**Extracellular flux measurements.** A Yellow Springs Instruments (YSI) 2950 was used to obtain extracellular flux measurements. Briefly, spent media was centrifuged at 300g for 5 min to remove cell debris. Culture medium supernatants were centrifuged at 15,000 RPM for 15 min to remove impurities and analyzed for glucose, lactate, glutamine and glutamate measurements. Amino acid uptake and secretion was calculated using GC-MS derivatization of fresh and spent media with internal labeled standards for quantification.

**Isotopomer spectral analysis.** Mass isotopomer distributions were determined by integrating metabolite ion fragments<sup>4</sup> summarized in **Supplementary Table 3** and corrected for natural abundance using in-house algorithms. ISA analysis was conducted using INCA<sup>46</sup> and a more complete model for fatty acid synthesis that accounted for production of myristate, palmitate, oleate and stearate (**Supplementary Table 1**).

**Cell culture and reagents.** All reagents were purchased from Sigma-Aldrich unless otherwise noted. All media and sera were purchased from Life Technologies unless otherwise stated. Murine 3T3-L1 pre-adipocytes were purchased from the American Type Culture Collection and cultured in high glucose Dulbecco's modified Eagle medium (DMEM) (Life Technologies) supplemented with 10% bovine calf serum (BCS) below 70% confluence. Cells were regularly screened for mycoplasma contamination. For differentiation,

10,000 cells/well were seeded into 12-well plates (ThermoFisher) and allowed to reach confluence (termed Day -2). On Day 0 differentiation was induced with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.25  $\mu\text{M}$  dexamethasone, 1  $\mu\text{g}/\text{ml}$  insulin, and 100 nM rosiglitazone in DMEM containing 10% FBS (FBS). Medium was changed on Day 2 to DMEM + 10% FBS with 1  $\mu\text{g}/\text{ml}$  insulin. Day 4, and thereafter DMEM + 10% FBS was used. Cobalamin (500 nM) or 5'-adenosylcobalamin (AdoCbl; 100 nM) were supplemented to cultures when noted.

**Human subjects.** Weight stable obese subjects undergoing elective laparoscopic gastric bypass via Roux-en-Y for the treatment of obesity were recruited for the study to provide material for pre-adipocyte isolation. The Institutional Review Boards of Scripps Memorial Hospital and the University of California, San Diego, approved the studies. All subjects gave informed consent.

**Adipose tissue (AT) biopsy.** Subcutaneous (S) AT biopsies were obtained from the superficial abdominal SAT depot and visceral (V) AT was obtained from the greater omentum<sup>25</sup>. Biopsy tissue was placed in a sterile HEPES salts solution as previously described<sup>47</sup> and transported to the lab for immediate processing.

**Human adipocyte differentiation.** Human pre-adipocytes were maintained in DMEM/F12 + 10% FBS. At Day 0 (2 days after confluence was reached), cells were differentiated in DMEM/F12 + 3% FBS, 0.5 mM IBMX, 100 nM insulin, 100 nM dexamethasone, 2 nM T3, 10  $\mu\text{g}/\text{ml}$  transferrin, 1  $\mu\text{M}$  rosiglitazone, 33  $\mu\text{M}$  biotin and 17  $\mu\text{M}$  pantothenic acid<sup>48</sup> induction cocktail for 7 days with medium changes every 2 days. After induction, cells were maintained in DMEM/F12 with 10 nM insulin and 10 nM dexamethasone until metabolic tracing experiments were conducted on Day 14.

**Tracing experiments.** All [<sup>13</sup>C] glucose and amino acid tracers were purchased from Cambridge Isotopes Inc. Stable isotope labeling of intracellular metabolites in differentiated 3T3-L1 cells was accomplished by culturing cells 7 days post-induction in tracer medium for 24 h unless otherwise stated. Proliferating 3T3-L1, A549, HuH-7 and 143B cells were seeded at 10,000 cells/cm<sup>2</sup> and cultured in tracer medium for 48 h. Custom DMEM or DMEM/F12 (Hyclone Laboratories, Inc.) was formulated with the specified tracer, unlabeled versions of other chemical components, and 10% dialyzed FBS such that all nutrients were available to cells in all experiments (with one or more labeled). Complete formulation of DMEM and Low gluc+AA media can be found in **Supplementary Table 3**. Mole percent enrichment (MPE) of isotopes was calculated as the percent of all atoms within the metabolite pool that are labeled:

$$\sum_{i=1}^n \frac{M_i \cdot i}{n}$$

where  $n$  is the number of carbon atoms in the metabolite and  $M_i$  is the relative abundance of the  $i$ th mass isotopomer.

**Gas chromatography/mass spectrometry (GC/MS) analysis.** Polar metabolites and fatty acids were extracted using methanol/water/chloroform and analyzed as previously described<sup>49</sup>. Proliferating 3T3-L1 cells and primary human adipocytes were cultured in 6-well plates, while differentiated 3T3-L1 cells were cultured in a 12-well plate and the volumes of extraction buffers were adjusted accordingly. Polar metabolites were derivatized in 20  $\mu\text{l}$  of 2% (w/v) methoxyamine hydrochloride (Thermo Scientific) in pyridine and incubated at 37  $^{\circ}\text{C}$  for 60–90 min. Samples were then silylated with 30  $\mu\text{l}$  of *N*-tert-butyltrimethylsilyl-*N*-methyltrifluoroacetamide (MTBSTFA) with 1% *tert*-butyldimethylchlorosilane (tBDMS) (Regis Technologies) at 37  $^{\circ}\text{C}$  for 30–45 min. Samples were centrifuged at 15,000 RPM for 5 min and supernatant was transferred to GC sample vials for analysis. Extracted nonpolar metabolites were evaporated, saponified and esterified to form fatty acid methyl esters (FAMES) through addition of 500  $\mu\text{l}$  2% (w/v)  $\text{H}_2\text{SO}_4$  in methanol and incubation at 50  $^{\circ}\text{C}$  for 90–120 min. FAMES were extracted after addition of 100  $\mu\text{l}$  saturated NaCl solution with two 500  $\mu\text{l}$  hexane washes and evaporated to dryness before redissolving in 50–100  $\mu\text{l}$  of hexane and transfer to glass GC vials

for analysis. Derivatized samples were analyzed by GC-MS using a DB-35MS column (30 m × 0.25 mm i.d. × 0.25 μm, Agilent J&W Scientific) installed in an Agilent 7890A gas chromatograph (GC) interfaced with an Agilent 5975C mass spectrometer (MS).

For quantitation of amino acids in plasma samples, an isotope-labeled internal standard mixture was prepared and added during extraction.

**Lentiviral production and shRNA KD of *Bckdha*.** Glycerol stocks of TRC2-pLKO.1-puro shRNA targeting mouse *Bckdha* (KD1: NM\_007533.2-421s1c1: CCGGTCCTTCTACATGACCAACTATCTCGAGATAGTTGGTCATGTAG AAGGATTTTTG; KD2: NM\_007533.2-1188s1c1: CCGGGCAGTCACGAAA GAAGGTCATCTCGAGATGACCTTCTTCGTGACTGCTTTTTG), and a non-targeting control construct were purchased from Sigma-Aldrich, packaged in HEK293T cells using the transfection agent Fugene 6 and required packaging plasmids VSV-G, gag/pol, and rev. HEK293T medium containing lentiviral constructs was collected two days later and filtered (0.45 μm). Polybrene was added to a final concentration of 6 μg/ml. 3T3-L1 pre-adipocytes were infected with 0.5 ml of virus-containing medium in a 6-well plate for 4 h before addition of 2 ml of virus-free medium. After 24 h of recovery, transduced cells were selected with 2 μg/ml puromycin. Cells were then plated to 12-well plates for differentiation as described above but without rosiglitazone. Puromycin was removed from the medium beginning on Day 0.

**RNA isolation and quantitative RT-PCR.** Total RNA was purified from cultured cells using Trizol Reagent (Life Technologies) per manufacturer's instructions. First-strand cDNA was synthesized from 1 μg of total RNA using iScript Reverse Transcription Supermix for RT-PCR (Bio-Rad Laboratories) according to the manufacturer's instructions. Individual 20 μl SYBR Green real-time PCR reactions consisted of 2 μl of diluted cDNA, 10 μl of SYBR Green Supermix (Bio-Rad), and 1 μl of each 5 μM forward and reverse primers. For standardization of quantification, 18S was amplified simultaneously. The PCR was carried out on 96-well plates on a CFX Connect Real time System (Bio-Rad), using a three-stage program provided by the manufacturer: 95 °C for 3 min, 40 cycles

of 95 °C for 10 s and 60 °C for 30 s. Gene-specific primers used are listed in **Supplementary Table 4**.

**Western blots.** 3T3-L1 adipocytes with Control KD or *Bckdha* KD were lysed in ice-cold RIPA buffer with 1× protease inhibitor (Sigma-Aldrich). 30 μg of total protein was separated on 12% SDS-PAGE gel. The proteins were transferred to a nitrocellulose membrane and immunoblotted with rabbit anti-Bckdha (Novus Biologicals NBPI-79616) (1:1,000 dilution) and mouse anti-Beta-Actin (Cell Signaling 8H10D10) (1:5,000). Specific signal was detected with horseradish peroxidase-conjugated secondary antibody goat anti-rabbit (1:2,500) or rabbit anti-mouse (1:10,000) using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and developed using Blue Devil Autoradiography film (Genesee Scientific).

**Statistical analysis.** Results shown as averages of technical replicates are presented as mean ± s.d. and are representative two or more independent experiments (biological replicates). Biological replicates are defined as separate experiments temporally; technical replicates are defined as separate spatial replicates (i.e., wells of a tissue culture plate) within an experiment. Respirometry results are averages of multiple independent experiments and presented as mean ± s.e.m. *P* values were calculated using Student's two-tailed *t* test or ANOVA, as required; \*, *P* value between 0.01 and 0.05; \*\*, *P* value between 0.001 and 0.01; \*\*\*, *P* value <0.001. Errors associated with MFA and ISA of lipogenesis are 95% confidence intervals determined via parameter continuation/sensitivity analysis.

46. Young, J.D. INCA: a computational platform for isotopically non-stationary metabolic flux analysis. *Bioinformatics* **30**, 1333–1335 (2014).
47. Phillips, S.A. *et al.* Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. *Am. J. Physiol. Endocrinol. Metab.* **297**, E767–E773 (2009).
48. Lee, M.-J.J., Wu, Y. & Fried, S.K. A modified protocol to maximize differentiation of human preadipocytes and improve metabolic phenotypes. *Obesity* **20**, 2334–2340 (2012).
49. Metallo, C.M. *et al.* Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature* **481**, 380–384 (2012).